PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

201.3B

Vuru Grade

72.50/100

Current Price

$31.95
-0.02 (-0.06%)

Growth Price

$30.64
Fairly valued

Stability Price

$11.67
Overvalued by 63.47%

Company Metrics

  • 19.72 P/E
  • 4.03 P/S
  • 2.58 P/B
  • 1.621 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1.04 / 3.25% Dividend
  • 26.00M Avg. Vol.
  • 6.30B Shares
  • 201.3B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.
Motley Fool - 10 hours ago
The largest pharmaceutical company in the world, Pfizer (NYSE: PFE ) , is a fixture in a number of retirement portfolios, and it's a staple holding of income investors looking for exposure to the healthcare sector.
Pfizer, Inc. Invests in Growth... Literally
Motley Fool - Dec 17, 2014
Pfizer Inc. (NYSE: PFE ) locked up commercial rights to Opko Health's (NYSE: OPK ) long-lasting human growth hormone in a deal worth hundreds of millions of dollars.
3 Reasons Pfizer, Inc. Could Soar in 2015
Motley Fool - Dec 11, 2014
Considering what a strong year it's been for health care stocks, especially biotech and pharmaceutical companies, Pfizer's (NYSE: PFE ) 7% year-to-date gains might leave a lot to be desired among shareholders. Pfizer struggled in 2014, as it has in ...
Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug
Bidness ETC - 10 hours ago
Pfizer Inc. (NYSE:PFE) yesterday announced positive results for its Phase III study evaluating pregabalin controlled-release (CR) treatment, marketed as Lyrica, as a treatment for postherpetic neuralgia, or pain due to nerve damage.
Stock Update: Pfizer Inc. (NYSE:PFE) - Street Report
Pfizer Is A Great Income Stock On A Pullback (PFE)
Seeking Alpha - Dec 18, 2014
Shareholders of pharma giant Pfizer (NYSE:PFE) have made a lot of money in the past few years. The company, which has generally been regarded as a yield play, has seen the value of its shares rise steadily since the stock consolidated under $20 three ...
Pfizer (NYSE:PFE) Obtains Commercial Rights to Human Growth Hormone - WallStreet.org
Pfizer Inc. (NYSE:PFE) Enrollment Of The First Patient In A Multicenter Phase ... - StreetWise Report
Pfizers Duchenne Muscular Dystrophy Drug in Phase II
Zacks.com - 23 hours ago
Pfizer Inc. (PFE - Analyst Report) enrolled the first patient in a multicenter phase II study on its experimental Duchenne muscular dystrophy (DMD) treatment, PF-06252616.
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy - Seeking Alpha
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy - Business Wire (press release)
iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for ...
MarketWatch - Dec 8, 2014
GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3 ...
Latest Top News Stories: Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Pfizer ... - Markets Emerging
5 Things Pfizer, Inc.'s Management Wants You to Know
Motley Fool - Nov 26, 2014
Pharmaceutical behemoth Pfizer (NYSE: PFE ) delivered its third-quarter earnings report late last month and all things considered it was pretty much in-line with Wall Street's expectations.
Will Pfizer Inc End Up Buying Bristol-Myers Squibb As Its Interest In ...
Bidness ETC - Dec 8, 2014
Mergers and acquisitions (M&A)-related activity in the healthcare sector this year appears to be never-ending. Word on the Street now is that Pfizer Inc. (NYSE:PFE) may be looking into acquiring its New York-based neighbor, Bristol-Myers Squibb Co ...
Stocks in the news: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company ... - Property Mentor
Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could ...
Motley Fool - Dec 1, 2014
Last week, Portola Pharmaceuticals (NASDAQ: PTLA ) reported interim results from a phase 3 trial of its drug andexanet alfa at the American Heart Association's Scientific Sessions 2014 conference -- results that could have big implications on Bristol ...